BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38190815)

  • 1. Transarterial Chemoembolization Combined with Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Pei X; Zhao J; Wang Z
    Oncology; 2024 Jan; ():. PubMed ID: 38190815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
    Liu JN; Li JJ; Yan S; Zhang GN; Yi PS
    Front Oncol; 2023; 13():1074793. PubMed ID: 36910612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
    Li D; Liu S; Cheng C; Xu L; Zhao P
    Medicine (Baltimore); 2023 Sep; 102(35):e34811. PubMed ID: 37657057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review.
    Yuanren G; Yin L; Liu R; Cui Y
    Front Oncol; 2023; 13():1054072. PubMed ID: 36969065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib in combination with transarterial chemoembolization vs. sorafenib in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma: A network meta‑analysis.
    Li Y; Liu X; Liu J; Yang L; Wei S; Li J; Gan H; Ma T; Yi P
    Oncol Lett; 2024 Aug; 28(2):347. PubMed ID: 38872858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
    Duan R; Gong F; Wang Y; Huang C; Wu J; Hu L; Liu M; Qiu S; Lu L; Lin Y
    World J Surg Oncol; 2023 Mar; 21(1):120. PubMed ID: 37004052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
    Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
    Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of TACE + Lenvatinib in Treating Advanced Hepatocellular Carcinoma: A Systematic Review and Meta- analysis.
    Pan D; Liu H; Ma X; Qu P; Cao M; Qin X; Tang J; Pan R; Huang Q; Han Z
    J Gastrointestin Liver Dis; 2023 Jun; 32(2):222-229. PubMed ID: 37345593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
    Wang L; Lin L; Zhou W
    Pharmacol Ther; 2024 May; 257():108634. PubMed ID: 38499069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of transarterial chemoembolization-lenvatinib sequential therapy for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study.
    Chen R; Li Y; Song K; Li L; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Apr; 13(2):780-786. PubMed ID: 35557575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
    Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
    Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of molecular targeted agents combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a network meta-analysis.
    Long J; Chen B; Liu Z
    Front Oncol; 2023; 13():1179431. PubMed ID: 37265792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score-Matched Analysis.
    Chen YX; Zhang JX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    J Hepatocell Carcinoma; 2022; 9():685-694. PubMed ID: 35937909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis.
    Xian F; Song XW; Bie J; Zhao CX; Zhang GJ; Xu GH
    Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):687-701. PubMed ID: 38305611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Zeng J; Lv L; Mei ZC
    Clin Res Hepatol Gastroenterol; 2016 Dec; 40(6):688-697. PubMed ID: 27339594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Liu J; Wei S; Yang L; Yu J; Yan D; Yi P
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):14451-14461. PubMed ID: 37563417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib plus transarterial chemoembolization
    Yang HJ; Ye B; Liao JX; Lei L; Chen K
    World J Hepatol; 2024 Jan; 16(1):91-102. PubMed ID: 38313249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
    Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.